MESD

Across TCGA pan-cancer cohorts, MESD mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of MESD’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where MESD mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types MESD is over-expressed in tumor, although a few such as PDAC show the opposite, repressed pattern.

CCRCC, PDAC, and LSCC are the cancer types where MESD tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MESD mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	All	II,III,IV	+0.218	<.001	9	view →
PDAC	Female	All	−0.500	<.001	8	view →
LSCC	Female	All	+0.351	<.001	8	view →
LUAD	Male	III,IV	+0.328	<.001	8	view →
HNSC	Male	IV	+0.296	<.001	8	view →
COAD	All	IV	+0.190	.044	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

MESD–CCRCC

Open the CCRCC breakdown →